Antitumorigenic effects of HIV protease inhibitor ritonavir: Inhibition of kaposi sarcoma

Blood

Volumn 99, Issue 10, 2002, Pages 3771-3779

  Pati, Shibani ^a,b,c   Pelser, Colleen B ^a,b,c   Dufraine, Joseph ^a,b,c   Bryant, Joseph L ^a,b,c   Reitz Jr , Marvin S ^a,b,c   Weichold, Frank F ^a,b,c  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c MORGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RITONAVIR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS LOAD;

EID: 0037093067     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.10.3771     Document Type: Article

References (75)

1. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group
2. Efficacy of combination antiretroviral therapy
3. Combination therapy with zidovudine, didanosine and saquinavir
4. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection
5. + cell counts despite persistently detectable HIV load
6. HIV treatment failure: Testing for HIV resistance in clinical practice
7. + T-cells and decreases their susceptibility to apoptosis in vitro
8. HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells
9. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo
10. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans
11. How an inhibitor of the HIV-1 protease modulates proteasome activity
12. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses
13. HIV-1 protease inhibitors. A review for clinicians
14. HIV-1 protease inhibitors
15. Regression of AIDS-related Kaposi's sarcoma following ritonavir therapy
16. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma
17. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group
18. Resolution of Kaposi's sarcoma associated with undetectable level of human herpesvirus 8 DNA in a patient with AIDS after protease inhibitor therapy
19. The natural history of Kaposi's sarcoma in the acquired immunodeficiency syndrome
20. AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects
21. AIDS. Viruses, cytokines and Kaposi's sarcoma
22. Production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1) in patients with AIDS, Enhanced level of TNF-alpha is related to a higher cytotoxic activity
23. Cytokines and acquired immunodeficiency syndrome
24. Production of interleukins in human immunodeficiency virus-1-replicating lymph nodes
25. Epidemiology and pathogenesis of Kaposi's sarcoma-associated herpes-virus
26. Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells
27. Role of Kaposi's sarcoma cells in recruitment of circulating leukocytes: Implications in pathogenesis
28. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma
29. Perspective on Kaposi's sarcoma: Facts, concepts, and conjectures
30. Angiogenic properties of human immunodeficiency virus type 1 Tat protein
31. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines
32. NF-kappa B: Ten years after
33. NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules
34. The NF-kappa B and I kappa B proteins: New discoveries and insights
35. Antiapoptotic mechanism of HIV protease inhibitor: Preventing mitochondrial transmembrane potential loss
36. The beta-core fragment of human chorionic gonadotrophin inhibits growth of Kaposi's sarcoma-derived cells and a new immortalized Kaposi's sarcoma cell line
37. Caspases: Intracellular signaling by proteolysis
38. Activation of the cell death program by inhibition of proteasome function
39. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers
40. An adhesion assay using minimal shear force to remove non-adherent cells
41. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator
42. Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression. Implications for AIDS-Kaposi's sarcoma pathogenesis
43. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation
44. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients
45. Activation of NFKB by the HHV-8 chemokine receptor ORF74: Evidence for a paracrine model of KS pathogenesis
46. The enigmas of Kaposi's sarcoma
47. Interleukin 6 induces the expression of vascular endothelial growth factor
48. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis
49. Cytokines and growth factors in the pathogenesis of AIDS-associated Kaposi's sarcoma
50. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression
51. Induction of apoptosis in fibroblasts by c-myc protein
52. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis
53. TNF-and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappaB
54. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB
55. Immunopathogenesis of Kaposi's sarcoma
56. Human immunodeficiency virus type 1 tat protein activates transcription factor NF-kappaB through the cellular interferon-inducible, double-stranded RNA-dependent protein kinase, PKR
57. Differential requirement for p56lck in HIV-tat versus TNF-induced cellular responses: Effects on NF-kappa B, activator protein-1, c-Jun N-terminal kinase, and apoptosis
58. Viral G protein-coupled receptor and Kaposi's sarcoma: A model of paracrine neoplasia?
59. Cytokines in HIV infection
60. Rel/NF-kappa B and I kappa B factors in oncogenesis
61. Rel/NF-kappaB/IkappaB proteins and cancer
62. Aberrant rel/nfkb genes and activity in human cancer
63. The transcription factor NF-kappaB: Control of oncogenesis and cancer therapy resistance
64. Bax degradation by the ubiquitin/proteasome-dependent pathway: Involvement in tumor survival and progression
65. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27
66. In vivo ubiquitination and proteasome-mediated degradation of p53(1)
67. Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells
68. Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway
69. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B
70. Proteasome inhibitors: A novel class of potent and effective antitumor agents
71. Proteasome inhibition: A new strategy in cancer treatment
72. Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma
73. Proteases as prognostic markers in cancer
74. The HIV protease inhibitor indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals